1. Home
  2. SEV vs PEPG Comparison

SEV vs PEPG Comparison

Compare SEV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SEV

Aptera Motors Corp.

N/A

Current Price

$2.58

Market Cap

103.2M

Sector

Industrials

ML Signal

N/A

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$1.82

Market Cap

121.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEV
PEPG
Founded
2019
2018
Country
United States
United States
Employees
46
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.2M
121.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SEV
PEPG
Price
$2.58
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.17
AVG Volume (30 Days)
225.7K
997.4K
Earning Date
05-16-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17,757.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$1.01
52 Week High
$11.24
$7.80

Technical Indicators

Market Signals
Indicator
SEV
PEPG
Relative Strength Index (RSI) 40.05 39.57
Support Level $2.49 $1.55
Resistance Level $3.26 $5.37
Average True Range (ATR) 0.15 0.14
MACD -0.04 0.12
Stochastic Oscillator 12.50 69.51

Price Performance

Historical Comparison
SEV
PEPG

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: